OncoSec Medical Incorporated (“OncoSec”) (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced the publication of new data in Clinical Cancer Research which highlighted TAVO™ (intratumoral plasmid IL-12 with electroporation) as a safe, feasibility and clinically meaningful therapy in patients with Merkel cell carcinoma (MCC), an aggressive form of skin cancer.
SAN DIEGO and PENNINGTON, N.J., Oct. 15, 2019 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (Nasdaq: ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced the publication of new data in Clinical Cancer Research which highlighted TAVO™ (intratumoral plasmid IL-12 with electroporation) as a safe, feasibility and clinically meaningful therapy in patients with Merkel cell carcinoma (MCC), an aggressive form of skin cancer. "These data demonstrate that intratumoral delivery of plasmid interleukin-12 with electroporation (TAVO™) as a monotherapy has the potential to have a durable impact on skin cancers such as Merkel cell carcinoma. I'm encouraged by these initial findings and believe that TAVO™ is a treatment approach that merits further exploration in MCC," commented Shailender Bhatia, M.D., associate professor, medical oncology, Department of Medicine, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, Washington and lead investigator and author of the study. The single-arm, open label pilot study evaluated 15 patients with MCC receiving TAVO™ intratumorally in two cohorts (Cohort A N=3 and Cohort B N=12). Cohort A patients had locoregional MCC and received one treatment cycle prior to a definitive surgery. Cohort B patients had metastatic MCC and received four cycles of TAVO™. Results showed that 25% of Cohort B patients experienced an overall response, with two patients receiving durable effect over 16 and 55+ months, respectively. Two Cohort A patients (one with pathologic complete remission) were recurrence-free at 44+ and 75+ months. "We continue to explore the broad therapeutic potential of TAVO™ across various cancer types and believe this study underscores the power of TAVO™ monotherapy in solid tumors such as MCC," said Daniel J. O'Connor, president and chief executive officer of OncoSec. "We remain encouraged by the growing body of clinical evidence for TAVO™ in multiple cancer indications both as a monotherapy and in combination with leading checkpoint inhibitors. We look forward to providing further data updates as we continue to advance our ongoing pivotal clinical trial with TAVO™ in metastatic melanoma and our phase 2 trial in triple negative breast cancer." An online version of the publication is available here: https://clincancerres.aacrjournals.org/content/early/2019/10/03/1078-0432.CCR-19-0972 About OncoSec Medical Incorporated TAVO™ is a registered trademark of OncoSec Medical Incorporated. Forward Looking Statements Company Contact:
SOURCE OncoSec Medical Incorporated |
||
Company Codes: NASDAQ-SMALL:ONCS |